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INTRODUCTION:  The  number  of patients  diagnosed  with  solid  carcinomas  is  increasing,  and  the  most
common  site  of  metastasis  is  the  lungs.  It is often  difﬁcult  to  make  a differential  diagnosis  between
primary  lung  carcinoma  and  metastatic  lung  tumor  in using  histological  examination  and  by  determining
their  immunohistological  status.
PRESENTATION:  A  64-years-old  man  presented  with  dyspnea  with  chest  computed  tomography  (CT)  ﬁnd-
ings of a pulmonary  tumor,  and  afterwards  suffered  from  a sudden  bowel  hemorrhaged  due  to  colorectal
carcinoma.  The  histological  diagnosis  of  a pulmonary  tumor  was  poorly  differentiated  adenocarcinoma.
Both  Thyroid  transcription  factor-1  (TTF-1)  and Cytokeratin20  (CK20)  were  immunohistologically  nega-
tive.  Of  the  some  oncogenic  mutations  investigated,  a  neuroblastoma  RAS  viral  oncogen  homolog  (NRAS)
codon13  G13D  mutation  was  detected  in  both  the  colorectal  carcinoma  and the  pulmonary  tumor  tissue
samples.  Based  on  the  result,  the  pulmonary  tumor  was diagnosed  as  a metastasis  derived  from  colorectal
carcinoma.
DISCUSSION:  Recently,  examination  of  the  oncogenes  of solid  carcinomas  has been  clinically  investigated
in  primary  lung  caricnoma  and  in  colorectal  carcinomas.  The  clinical  advantage  of  the  oncogenic  mutation
survey  is to identify  the  site,  and  the  type,  of amino  acid  change  in detail.  This  case  is  a  rare  successful
case  of a  survey  of the oncogenes  for giving  a differential  diagnosis.
CONCLUSION:  A survey  of  the  oncogenic  genes  is  very  useful  to make  a  differential  diagnosis  between
primary  lung  carcinoma  and metastatic  lung  tumor.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
The number of patients diagnosed with solid carcinomas is
ncreasing, and the most common site of metastasis is the lungs. It is
ften difﬁcult to give a differential diagnosis between primary lung
arcinoma and metastatic lung tumor [1], especially in the case of
olitary pulmonary tumor with lymphadenopathy. In these cases,
linical diagnosis is made using histological examination of the
umor and by determining their immunohistological status using
peciﬁc markers, such as TTF-1. However, both diagnostic methods
re inexact, and so, most patients with undifferentiated pulmonary
umors are treated using empirical chemotherapy regimens.
Recently, examination of the oncogenes of solid carcinomas,
ncluding primary lung carcinoma, has been undertaken. Epidermal
rowth factor receptor (EGFR) mutation or anaplastic lymphoma
ecptor (ALK) rearrangement has been clinically investigated in
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primary lung adenocaricnoma, and the Kirsten rat sarcoma viral
oncogen homolog (KRAS) and NRAS mutations have been investi-
gated in colorectal carcinomas. As such, patients with wild KRAS
beneﬁt from treatment using anti-EGFR therapies, such as panitu-
mumab  or cetuximab [2]. In the present case study, we present a
case of successful diagnosis of a metastatic lung tumor derived from
colorectal carcinoma by a survey of the oncogenic gene, NRAS.
2. Case report
A 64-years-old man  presented with dyspnea. He had acute car-
diac insufﬁciency, and chest X-ray and chest CT showed cardiac
dilatation and a right side pulmonary tumor with right mediastinal
and hilar lymphadenopathy and bilateral pleural effusion. Follow-
ing his recovery from the acute cardiac insufﬁciency, he suffered
from a sudden bowel hemorrhaged due to colorectal carcinoma
(Fig. 1). The hemorrhage was locally controlled using radiation
therapy (40 Gy/16 Fr) combined with oral S-1. After recovery from
the heart failure and bowel hemorrhage, chest CT revealed that
the size of the pulmonary tumor had increased in size to 10.4 cm
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Panel A: Colonoscopy revealed a bowel hemorrhage from the colorectal carcinoma. Panel B: Hematoxylin-eosin stain showed well-to-moderately differentiated
tubular  adenocarcinoma. (×200).
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ed  arrows), hilar (D; yellow arrowheads) and mediastinal (B and C; red arrowhead
Fig. 2). A tissue biopsy of the pulmonary tumor was  performed
ia bronchoscopy (Fig. 3A). The histological diagnosis was poorly
ifferentiated adenocarcinoma (Fig. 3B). We  could not make a dif-
erential diagnosis between primary lung carcinoma and metastatic
ung tumor from colorectal carcinoma because both TTF-1 and
K20 were immunohistologically negative (Fig. 3C and D). As
uch, chemotherapy of carboplatin and irinotecan was given to the
atient as irinotecan is effective for both primary lung carcinoma
nd colorectal carcinoma.d the tumor. Panel B, and C and D: Chest CT revealed a pulmonary tumor(C and D;
phadenopathy is enhanced by contrast medium.
To make a more informed diagnosis, we furthermore investi-
gated the EGFR mutation and ALK rearrangement of the primary
lung carcinoma, and the KRAS and NRAS mutations of the colorec-
tal carcinoma. Of the oncogenic mutations investigated, a NRAS
codon13 G13D mutation was  detected in both the colorectal car-
cinoma and the pulmonary tumor tissue samples. Based on the
result, the pulmonary tumor was diagnosed as a metastasis derived
from colorectal carcinoma. Four cycles of chemotherapy resulted
in a partial response until a new bone metastasis appeared in the
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cig. 3. Panel A: Bronchoscopy revealed the tumor in the segmental bronchus B5 of
anel  B: Hematoxylin-eosin stain shows poorly differentiated adenocarcinoma (×20
re  negative in the pulmonary tissue sample (×200).
eft iliac bone. After additional radiotherapy to the iliac bone for
he relief of pain, the patient was administered bevasizmab and
FOLFOX6 for three cycles, which resulted in a diagnosis of stable
isease.
. Discussion
The number of patients with solid carcinomas is increasing, and
ne of the most common metastasis sites is the lungs. In the clinic,
t is often difﬁcult to differentiate between primary lung carcinoma
nd a metastatic lung tumor [1]. In these cases, clinical diagnosis is
ade based on histological examination of the tumor or by deter-
ining the immunohistological status of the tumor using speciﬁc
arkers, such as TTF-1. In the present case study, the immunohis-
ological markers TTF-1 and CK20 were not useful in the diagnosis
ecause the markers were negative in the pulmonary tumor. TTF-1
s negative in 15.5% of primary lung adenocarcinoma and positive
n 87.5% of pulmonary metastatic adnocarcinoma [3]. In addition,
he CK20 marker for colorectal carcinoma is negative in 40% of
ulmonary metastasises derived from colorectal carcinoma [4].
Of the oncogenic mutations that were investigated, we found
hat the NRAS mutation was detected in both the colorectal carci-
oma and pulmonary tumor tissue. From the frequency and sites
f the mutations, and the amino acid changes of NRAS, we deter-
ined that the pulmonary tumor was a metastatic lung tumor
rising from a colon carcinoma. The frequency of NRAS mutations
n primary lung carcinoma is reported to be either 0.7% [5] or 0.5%
6], which makes it extremely rare. In contrast, the frequency of
RAS mutations is reported to be 2.6% in colorectal carcinoma [7].
n another study, the frequency of mutations was found to be 5.1%
n colorectal carcinomas with wild-type KRAS codons 12 and 13
8]. Of course, NRAS mutations are frequently observed in some
olid carcinoma or hematological malignancies [9], and there is the
ossibility that both the colorectal carcinoma and the primary lung
arcinoma might both contain NRAS mutation, but that they mayight middle lobe. There was no ﬁnding of hemorrhage from the pulmonary tumor.
nel C and D: Immunohistological staining showed that both TTF-1 (C) and CK20 (D)
no be derived from each other. However, it is more likely that the
pulmonary tumor in this case was  a pulmonary metastasis from the
NRAS-positive colorectal carcinoma, because of the similarities in
the NRAS mutations of both tumors. For colorectal carcinomas, the
similarity of the KRAS and BRAF mutations between primary and
metastatic tumor tissue samples was  reported to be 100% [2]. In
addition, we suggest that the advantage of the oncogenic mutation
survey is to identify the site, and the type, of amino acid change
in detail. For colorectal carcinoma, the nucleotide changes occur in
codons 12,13 and 16, and the amino acid changes are Q61K/R/L,
G12D/C/S and G13D [8] .In contrast, for primary lung carcinoma,
the amino acid changes are Q61H/K/L/R (exon3), and G12A/C/D/R/S
(exon2) [5]. CodonQ61 is the most frequent mutation of NRAS-
positive primary lung carcinoma (81%), and around half of the
mutation is in NRASQ61L [5]. To our knowledge, until now no study
examining mutations in codon13 G13D has been reported.
RAS/RAF/MEK mutations are known to be mediators of acquired
resistance in some solid tumors, such as: colorectal carcinoma, gas-
trointestinal stromal tumors, and melanoma. These type of cancer
be responsive to targeted therapies [10], and there remains the pos-
sibility that the NRAS mutation in primary lung carcinoma might
be a secondary mutation associated with resistance to drug ther-
apy. However, the signiﬁcance of NRAS varies between primary
lung carcinoma and colorectal carcinomas. In a previous study that
examined the frequency of secondary KRAS/KRAS/BRA/MEK1 gene
mutations in primary lung carcinoma with acquired resistance to
EGFR TKI [10], no NRAS, KRAS,or MEK1 mutations were detected,
except for two cases of BRAF mutations [10] .For primary lung car-
cinoma, NRAS mutations are thought to be mutually exclusive with
other known driver mutations, including EGFR, KRAS, and ALK [5],
and they are thought to be one of the mechanisms of lung adeno-
carcinoma ontogenesis, even if it is a very rare event [6].
Currently, most patients with undiagnosed pulmonary tumors
are treated with empirical chemotherapy regimens, and examina-
tion of the mutations in primary and pulmonary tumors is useful
 –  O
f Surg
i
t
4
c
m
C
F
E
C
p
A
t
F
[
O
T
p
cCASE  REPORT
A. Haro et al. / International Journal o
n making an accurate diagnosis, and in selection of more effective
reatment.
. Conclusions
It is often difﬁcult to differentiate between a primary lung car-
inoma and a metastatic lung tumor. Examination of oncogenic
utations is a useful in the diagnosis of pulmonary tumors.
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